Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
| Revenue (TTM) | 1,000 |
| Gross Profit (TTM) | 1,000 |
| EBITDA | $-11.69M |
| Operating Margin | 0.00% |
| Return on Equity | -320.70% |
| Return on Assets | -105.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.73 |
| Price-to-Book | 0.67 |
| Price-to-Sales (TTM) | 7.23 |
| EV/Revenue | 11.47 |
| EV/EBITDA | -0.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -94.10% |
| Shares Outstanding | $1.63M |
| Float | $1.22M |
| % Insiders | 27.73% |
| % Institutions | 2.44% |
Volatility is currently contracting
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa's platform and member of Ernexa's Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET
Preclinical data highlighting ERNA-101's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston Preclinical data highlighting ERNA-101's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector
Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics
ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology
President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass.
Video webcast now available here
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ERNA and any ticker you trade — then tracks every position and per-strategy win rate.
